Implementation and Audit of Mainstream Genetic Testing Within a High‐Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/2657384 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, online erschienen am 27.07.2026. Verfasst von Soraya Conroy und 17 weiteren Autor:innen. Beteiligte Einrichtung: Breast Unit, Royal United Hospital, Bath, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Testing. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
It is estimated that 5%–10% of patients who develop breast cancer have a causative inherited pathogenic or likely pathogenic variant (P/LP variant). In 2020, the UK National Test Directory published criteria for mainstream genetic testing for breast cancer patients (R208) and, subsequently, eligibility criteria to determine which patients are eligible for gene testing and PARP inhibitor treatment (R444.1).
Methods
Using the clearly defined criteria from NHS genomics, eligibility for testing under R208/R444.1 was determined for all patients diagnosed with breast cancer between March 2021 and March 2025. Eligible patients were offered genetic testing. Incidence of P/LP variants and impact on treatment were examined.
Results
A total of 1812 patients had new DCIS/invasive breast cancer diagnoses, 255 were eligible for testing and 196 consented. Of these, 28 patients (14.3%) had a P/LP variant. Eight of these patients were eligible only using family history criteria. Twenty‐one patients were eligible for breast conservation surgery. Preoperative genetic results were available for 13: eight patients opted for bilateral mastectomy rather than breast conservation. Where results were available postoperatively, three of eight patients who had breast conservation are planning bilateral risk reducing surgery. Three women newly diagnosed with a BRCA variant received a PARP inhibitor. Eligibility assessment for testing was time‐consuming for trained clinicians.
Conclusion
14.3% of patients eligible and tested for a breast cancer–related hereditary P/LP variant were positive, which aligns with the expected number predicted by Genomics England. Family history scoring is an important element. Positive results were associated with changes in surgical decision‐making for 14 women and enabled 3 patients to receive a PARP inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Breast Unit, Royal United Hospital, Bath, UK.
- Computer Science Department, University of Bristol, Bristol, UK, bristol.ac.uk.
- Medical School, University of Bristol, Bristol, UK, bristol.ac.uk.
ORCID-Profile: Nicola Laurence
Zitieren
APA
Conroy, S., Keane, E., Rehman, B., Wyborn, E., Brown, C., Chen, L., Chatten, J., Durston-Rand, E., Sheehan, B., Ferguson, E., Miles, T., Beck, E., Hunter-Smith, A., Laban, C., Smith, K., Dalgliesh, D., Bowen, R., & Laurence, N. (2026). Implementation and Audit of Mainstream Genetic Testing Within a High‐Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion. The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/2657384
Vancouver
Conroy S, Keane E, Rehman B, Wyborn E, Brown C, Chen L, et al. Implementation and Audit of Mainstream Genetic Testing Within a High‐Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion. The Breast Journal. 2026;2026(1). doi:10.1155/tbj/2657384
BibTeX
@article{Conroy2026,
author = {Conroy, Soraya and Keane, Emma and Rehman, Bushra and Wyborn, Eleanor and Brown, Catherine and Chen, Lamb and Chatten, Josh and Durston-Rand, Elijah and Sheehan, Blaise and Ferguson, Elizabeth and Miles, Tracie and Beck, Emma and Hunter-Smith, Alison and Laban, Christiana and Smith, Katherine and Dalgliesh, Diana and Bowen, Rebecca and Laurence, Nicola},
title = {Implementation and Audit of Mainstream Genetic Testing Within a High‐Volume UK Breast Unit for Pathogenic Variations Associated With Breast Cancer Using the R208 and R444.1 National Test Directory Criterion},
journal = {The Breast Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbj/2657384}
}
EUVIMED